SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (23939)6/11/2007 2:52:43 PM
From: IRWIN JAMES FRANKEL  Respond to of 52153
 
We did see some data on variations in batches of L which seemed surprisingly wide to me.

It would seem that if someone could tighten the range and keep it within the bounds of the approved drug that it would makes sense to approve it.

ij



To: Arthur Radley who wrote (23939)6/11/2007 3:03:59 PM
From: rkrw  Read Replies (1) | Respond to of 52153
 
Exactly. Maybe the innovators drugs should never have been approved in the first place. Or in mnta's case, let the fda approve the better controlled and more consistent generic (mLovenox) and pull sanofi's approval :-)

Innovator idea of course is the variability would block any generic from ever being approved. Who needs patent protection when you have batch to batch variability!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News